Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.
Sanofi has experienced a series of internal setbacks on the R&D front in recent months, but its close partnership with Regeneron is still paying off with promising late-stage data.
Bristol-Myers Squibb's little-discussed rheumatoid arthritis drug clazakizumab posted strong results in a mid-stage study, meeting its endpoints, notching promising remission data and stirring hopes that the treatment can compete with AbbVie's blockbuster Humira.
Isis Pharmaceuticals has opted to throw in the towel on its rheumatoid arthritis program for ISIS-CRP Rx, but the biotech says it will continue to plug away at studies of the antisense treatment for other diseases, including a mid-stage trial for atrial fibrillation due to read out next year.
Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.
AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to scrap its development efforts and turn the whole program back over to Rigel, the biotech partner which had licensed it to them in the first place
European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about the risk-benefit profile. The surprise rejection cools the company's run of regulatory success, which included 5 FDA approvals in 2012.
The London drug giant missed one out of two main goals for the study of fostamatinib, leaving the prospects of the candidate open to skepticism after it fell short of matching the efficacy of AbbVie's Humira in an earlier mid-stage trial.
Pfizer has quietly grabbed rights to an experimental "armed antibody" in early human testing against rheumatoid arthritis, with interest in advancing the candidate from the Italy-based biotech Philogen for inflammatory bowel disease, according to Philogen's release from yesterday.
AstraZeneca isn't the only pharma giant having problems with rheumatoid arthritis today. Eli Lilly threw in the towel on one of three Phase III studies of an experimental antibody for patients with RA after an interim analysis showed lack of efficacy.